Beta%252525252520blockers

# Beta Blockers ## Overview Beta-adrenergic blocking agents competitively antagonize catecholamine binding to beta-adrenergic receptors. They are categorized as non-selective (e.g., propranolol), cardioselective (beta-1 selective; e.g., metoprolol, bisoprolol), or those with additional alpha-blocking/vasodilatory properties (e.g., carvedilol, labetalol). ## Primary Indications * Hypertension * Angina pectoris * Heart failure with reduced ejection fraction (HFrEF) * Post-myocardial infarction (secondary prevention) * Tachyarrhythmias (atrial fibrillation/flutter) * Migraine prophylaxis (propranolol) * Essential tremor (propranolol) ## Adult Dosing * **Metoprolol Succinate (ER):** Start 25–50 mg daily; titrate to max 200 mg daily for HF. * **Metoprolol Tartrate (IR):** 25–100 mg BID. * **Carvedilol:** Start 3.125 mg BID; titrate to max 25 mg BID (if weight <85kg) or 50 mg BID (if >85kg) for HF. * **Bisoprolol:** Start 1.25–2.5 mg daily; max 10 mg daily. * **Propranolol (ER):** 80 mg daily; titrate to 240 mg daily for migraine/HTN. ## Pediatric Dosing * **Propranolol (Hypertension/Tachycardia):** Start 0.5–1 mg/kg/day divided BID-TID; range 2–4 mg/kg/day. Max 16 mg/kg/day. * **Atenolol:** 0.5–1 mg/kg/day once daily. * *Note: Dosing is highly variable based on indication (e.g., infantile hemangioma vs. HTN). Refer to institutional protocols (e.g., Harriet Lane).* ## Dose Adjustments * **Renal Impairment:** Atenolol requires significant dose reduction; lipophilic agents (metoprolol, propranolol) undergo extensive hepatic metabolism and rarely require dosage adjustment. * **Hepatic Impairment:** Reduce initial doses for propranolol and carvedilol due to extensive first-pass metabolism. ## Contraindications * Second or third-degree AV block (without a pacemaker). * Severe bradycardia (typically <50 bpm). * Decompensated heart failure (unless stable, low-dose initiated). * Cardiogenic shock. * Severe reactive airway disease (bronchospastic asthma—use caution with non-selective agents). ## Adverse Effects * **Common:** Bradycardia, hypotension, fatigue, dizziness, sexual dysfunction. * **Metabolic:** May mask symptoms of hypoglycemia (tachycardia) and impair glycemic control in diabetic patients. * **Psychiatric:** Depression, insomnia, vivid dreams (notably propranolol). ## Key Drug Interactions * **CYP2D6 Inhibitors:** (e.g., fluoxetine, paroxetine) increase levels of metoprolol and carvedilol. * **Non-DHP Calcium Channel Blockers:** (e.g., diltiazem, verapamil) risk of additive AV block and severe bradycardia. * **Digoxin:** Additive slowing of AV nodal conduction. ## Monitoring * **HR and BP:** Prior to every dose during titration. * **HF Patients:** Monitor for signs of fluid overload (weight gain, edema) during initiation due to negative inotropic effects. * **Diabetics:** Monitor blood glucose patterns. ## Clinical Pearls * **Abrupt Withdrawal:** Never discontinue beta-blocker therapy abruptly, especially in patients with ischemic heart disease, to avoid rebound hypertension or myocardial infarction. Taper over 1–2 weeks. * **Lipophilicity:** Propranolol is highly lipophilic (CNS penetration), making it effective for tremors/migraines but associated with higher rates of CNS side effects. * **Cardioselectivity:** Selectivity for beta-1 receptors is dose-dependent; at high doses, cardioselectivity is often lost. *** **Disclaimer:** This information is for educational purposes only. Always verify dosing, contraindications, and drug interactions using official product labeling, institutional protocols, or clinical decision support tools (e.g., Lexicomp, UpToDate) before prescribing or administering medication.